Medical News Hubb
Advertisement
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us
No Result
View All Result
Medical News Hubb
No Result
View All Result
Home Medicines & Healthy Lifestyle

FDA Approves Room Temp Storage Conditions for Asceniv and Bivigam

admin by admin
December 15, 2022
in Medicines & Healthy Lifestyle


The Food and Drug Administration (FDA) has approved the supplemental Biologics LIcense Applications for both Asceniv™ (immune globulin intravenous [human] – slra) 10% Liquid and Bivigam® (immune globulin intravenous [human]) 10% Liquid to now include room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life. 

The new room temperature storage condition for Asceniv and Bivigam is immediately effective, and applies to all existing lots currently in the commercial supply chain and to future production.

Asceniv and Bivigam are indicated for the treatment of primary humoral immunodeficiency in adults and adolescents (12 to 17 years of age). Primary immunodeficiency includes, but is not limited to, the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. 


Continue Reading

Asceniv is supplied as a liquid solution containing 10% IgG (100mg/mL) in a 50mL single-use vial. Bivigam is supplied as a liquid solution containing 10% IgG (100mg/mL) in a 50mL and 100mL single-use vial. 

“With today’s announced approval, the Company anticipates reaching more customers otherwise inaccessible due to limited refrigeration space and cold chain capacity constraints; this approval meaningfully alleviates these supply chain restrictions,” said Adam Grossman, President and CEO of ADMA. “The approval of room temperature storage for Asceniv and Bivigam is a meaningful enhancement of each product’s go-to market offering as it should provide for more versatile utilization and inventory management by providers.”

Reference

ADMA Biologics announces FDA approval for room temperature storage of Asceniv™ & Bivigam®. News release. ADMA Biologics. Accessed December 13, 2022. https://www.globenewswire.com/news-release/2022/12/13/2572541/33130/en/ADMA-Biologics-Announces-FDA-Approval-for-Room-Temperature-Storage-of-ASCENIV-BIVIGAM.html.

This article originally appeared on MPR

Topics:

Immune Disorders
Miscellaneous Immune Disorders



Source link

Previous Post

Routine LMWH Failed to Improve Live Births in Inherited Thrombophilia

Next Post

A new benchmark: National average drug acquisition cost

Next Post

A new benchmark: National average drug acquisition cost

Recommended

Genentech finds no fraud in paper by former top exec

April 7, 2023

Neuroscientist Explains Two Simple Exercises To Improve Vision

February 27, 2023

Don't miss it

Pharmaceutical

Merck sues U.S. government over Medicare negotiation program

June 6, 2023
Medicines & Healthy Lifestyle

Could This Common Supplement Be the Answer to Tumors?

June 6, 2023
Medicines & Healthy Lifestyle

Sad Songs Have Positive Effects On A Person’s Well-Being, Study Suggests

June 6, 2023
News

FDA Delays Decision on SpringWorks Therapeutics’ Tumor Treatment

June 6, 2023
Pharmaceutical

Alkem Gets CDSCO Panel Nod to Study Antidiabetic FDC Drug

June 6, 2023
Pharmaceutical

BIO taps Global Blood Therapeutics’ Ted Love as board chair

June 5, 2023

© Medical News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

Newsletter Sign Up

No Result
View All Result
  • Home
  • News
  • Pharmaceutical
  • Medicines & Healthy Lifestyle
  • Contact us

© 2022 Medical News Hubb All rights reserved.